GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mosaic ImmunoEngineering Inc (OTCPK:CPMV) » Definitions » Total Assets

CPMV (Mosaic ImmunoEngineering) Total Assets : $0.14 Mil (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Mosaic ImmunoEngineering Total Assets?

Mosaic ImmunoEngineering's Total Assets for the quarter that ended in Dec. 2024 was $0.14 Mil.

During the past 12 months, Mosaic ImmunoEngineering's average Total Assets Growth Rate was 3.00% per year. During the past 3 years, the average Total Assets Growth Rate was -54.00% per year. During the past 5 years, the average Total Assets Growth Rate was -44.90% per year. During the past 10 years, the average Total Assets Growth Rate was -22.70% per year.

During the past 13 years, Mosaic ImmunoEngineering's highest 3-Year average Total Assets Growth Rate was 149.20%. The lowest was -73.10%. And the median was -12.10%.

Total Assets is connected with ROA %. Mosaic ImmunoEngineering's annualized ROA % for the quarter that ended in Dec. 2024 was -672.53%. Total Assets is also linked to Revenue through Asset Turnover. Mosaic ImmunoEngineering's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.


Mosaic ImmunoEngineering Total Assets Historical Data

The historical data trend for Mosaic ImmunoEngineering's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mosaic ImmunoEngineering Total Assets Chart

Mosaic ImmunoEngineering Annual Data
Trend May15 May16 May17 May18 May19 May20 Dec21 Dec22 Dec23 Dec24
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.82 0.27 0.26 0.18 0.14

Mosaic ImmunoEngineering Quarterly Data
Feb20 May20 Aug20 Nov20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.08 0.01 0.04 0.14

Mosaic ImmunoEngineering Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Mosaic ImmunoEngineering's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=-6.788+6.93
=0.14

Mosaic ImmunoEngineering's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (Q: Dec. 2024 )+Total Liabilities (Q: Dec. 2024 )
=-6.788+6.93
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mosaic ImmunoEngineering  (OTCPK:CPMV) Total Assets Explanation

Total Assets is connected with ROA %.

Mosaic ImmunoEngineering's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %=Net Income (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=-0.612/( (0.04+0.142)/ 2 )
=-0.612/0.091
=-672.53 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Mosaic ImmunoEngineering's Asset Turnover for the quarter that ended in Dec. 2024 is

Asset Turnover
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0/( (0.04+0.142)/ 2 )
=0/0.091
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Mosaic ImmunoEngineering Total Assets Related Terms

Thank you for viewing the detailed overview of Mosaic ImmunoEngineering's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Mosaic ImmunoEngineering Business Description

Traded in Other Exchanges
N/A
Address
9114 Adams Avenue, Suite 202, Huntington Beach, CA, USA, 92646
Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. It has a single operating segment for the purposes of assessing performance and making operating decisions.
Executives
Robert Baffi director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Case Western Reserve University 10 percent owner 10900 EUCLID AVENUE, CLEVELAND OH 44106
Steven W King director, officer: President and CEO
Paul J Lytle director, officer: EVP, Chief Financial Officer
Robert L Garnick director C/O PATRIOT SCIENTIFIC, 2038 CORTE DEL NOGAL, SUITE 141, CARLSBAD CA 92011
Nicole Franziska Steinmetz director, officer: Chief Scientific Officer 871 WILBUR AVENUE, SAN DIEGO CA 92019
Dharmesh Mistry director 315 PEMBROKE COURT, SAN RAMON CA 94582
Carlton M Johnson director
Donald E Schrock director C/O INTEGRATED DEVICE TECHNOLOGY, INC., 6024 SILVER CREEK VALLEY ROAD, SAN JOSE CA 95138
Paul R Bibeau officer: VP, Business Development MICROSEMI CORP, 2381 MORSE AVE, IRVINE CA 92614
Frederick C Goerner officer: Chief Executive Officer MICROSEMI CORPORATION, ONE ENTERPRISE, ALISO VIEJO CA 92656
Clifford L Flowers officer: Chief Financial Officer C/O BAKBONE SOFTWARE, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Harry L Tredennick director 6183 PASEO DEL NORTE #180, CARLSBAD CA 92011
Thomas J Sweeney officer: CFO
Helmut Jr Falk director

Mosaic ImmunoEngineering Headlines

From GuruFocus

Patriot Scientific Corporation Files Quarterly Report

By ACCESSWIRE AccessWire 04-12-2019

Patriot Scientific Corporation Files Quarterly Report

By ACCESSWIRE AccessWire 04-12-2019